← Back to patent-cliff list
辛伐他汀
Tier C — Watch / tradeSimvastatin
默沙东
Originator
1988
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：HMGCR
Brand：Colemin、Lodalès、Lipex、Lipovas、舒降之、Zocord、Sinvacor、Denan、Zocor、Simvast CR、Pantok、Sivastin、Medipo
Indications (approved)：高脂血症、心肌梗塞、血脂障碍、杂合子家族性高胆固醇血症、中风、高胆固醇血症、高脂蛋白血症Ⅴ型、冠状动脉疾病
Regional status
US
批准上市
1991-12-23
EU
临床三期
1998-07-01
China
批准上市
1997-01-01
Japan
批准上市
1991-12-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Simvastatin?
Approved indications include: 高脂血症, 心肌梗塞, 血脂障碍, 杂合子家族性高胆固醇血症, 中风, 高胆固醇血症, 高脂蛋白血症Ⅴ型, 冠状动脉疾病.
When does the Simvastatin patent expire?
No public expiry year is available for Simvastatin yet; this page updates once verified.
How do I get a quote for Simvastatin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25